Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 versus ketamine in treatment-resistant depression
2018-003002-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of onfasprodil in major depressive disorder (MDD) (2 arms), sponsored by Novartis. Primary endpoint: Total MADRS score. Started Apr 2019; status: completed.
02
Drugs
onfasprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-003002-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003002-12.